Abstract
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
Keywords: Cancer immunotherapy, combination therapy, indoleamine 2, 3-dioxygenase (IDO), IDO inhibitors, immune tolerance.
Current Cancer Drug Targets
Title:Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Volume: 16 Issue: 9
Author(s): Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin
Affiliation:
Keywords: Cancer immunotherapy, combination therapy, indoleamine 2, 3-dioxygenase (IDO), IDO inhibitors, immune tolerance.
Abstract: Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
Export Options
About this article
Cite this article as:
Selvan R. Senthamil, Dowling P. John, Kelly K. William and Lin Jianqing, Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009615666151030102250
DOI https://dx.doi.org/10.2174/1568009615666151030102250 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Novel Targets in Cancer Immunotherapy
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly revolutionized therapeutic strategies in the field of cancer. Current targets of FDA-approved ICIs include CTLA-4, PD-1/PDl-1, and LAG-3. However, the prognosis of cancer patients, especially with solid tumors, remains unfavorable due to the intrinsic and acquired resistance. For the past decades, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design The Role of Aromatase Enzyme in Hormone Related Diseases and Plant- Based Aromatase Inhibitors as Therapeutic Regimens
Current Topics in Medicinal Chemistry Proteomic Classification of Breast Cancer
Current Drug Targets The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Management of Unusual Not Scar Ectopic Pregnancy: A Multicentre Retrospective Case Series
Current Women`s Health Reviews Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility
Current Women`s Health Reviews Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM
Current Cancer Drug Targets DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives
Current Molecular Pharmacology Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy
Current Cancer Drug Targets Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells
Recent Patents on Regenerative Medicine Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer
Current Medicinal Chemistry Impact of IL-12 in Cancer
Current Cancer Drug Targets Current Perspectives on Paclitaxel: Focus on Its Production, Delivery and Combination Therapy
Mini-Reviews in Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design